The 40th JPM 2022 Healthcare Conference was held from January 10th to 13th, with digital meetings continuing until the end of January, enabling exchanges among pharmaceutical companies from around the world.
This meeting brought together a large number of domestic pharmaceutical and bio companies, including Samsung Biologics, making it an occasion to discuss global technology transfers.
With many domestic companies participating in the main track, emerging track, and Asia-Pacific sessions, RudaCure was also able to continue discussions on RCI001 and RCI002 with interested parties including Kintor, Qilu, Alimera Sciences, and AbbVie through this JPM conference.
Among these, AbbVie expressed significant interest in RCI001, showing great enthusiasm for the clinical trial progress and expressing amazement at the drug's efficacy through its novel mechanism of action, hoping to establish an ongoing relationship. Chinese companies were also able to exchange information about market conditions in China.